Anti-tumor effect of innovative tumor treatment device OM-100 through enhancing anti-PD-1 immunotherapy in glioblastoma growth
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Anti-tumor effect of innovative tumor treatment device OM-100 through enhancing anti-PD-1 immunotherapy in glioblastoma growth ; volume:14 ; number:1 ; day:8 ; month:8 ; year:2024 ; pages:1-10 ; date:12.2024
Scientific reports ; 14, Heft 1 (8.8.2024), 1-10, 12.2024
- Creator
-
Yan, Zhaoxian
Huang, Lifa
Zhang, Xin
Yu, Xinyan
Huang, Rui
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-024-67437-4
- URN
-
urn:nbn:de:101:1-2410272119148.592761370937
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Yan, Zhaoxian
- Huang, Lifa
- Zhang, Xin
- Yu, Xinyan
- Huang, Rui
- SpringerLink (Online service)
Other Objects (12)
Targeting CD73 limits tumor progression and enhances anti-tumor activity of anti-PD-1 therapy in intrahepatic cholangiocarcinoma
Anti-PD-1 antibody armored γδ T cells enhance anti-tumor efficacy in ovarian cancer
Proactive over reactive: the snare-based pretraction method improving the full-thickness resection of a large gastrointestinal stromal tumor
Targeted Anti‐Tumor Immunotherapy Using Tumor Infiltrating Cells
TH9 cells in anti-tumor immunity
Reversible acute blindness in suspected metformin-associated lactic acidosis: a case report
Targeting tumor cells with antibodies enhances anti-tumor immunity
Melatonin: an anti-tumor agent for osteosarcoma
Golimumab: A Novel Anti-Tumor Necrosis Factor
Tumor ablation induced anti-tumor immunity: destruction of the tumor in situ with the aim to evoke a robust anti-tumor immune response
Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC
Estrogen/ER in anti-tumor immunity regulation to tumor cell and tumor microenvironment
Targeting CD73 limits tumor progression and enhances anti-tumor activity of anti-PD-1 therapy in intrahepatic cholangiocarcinoma
Anti-PD-1 antibody armored γδ T cells enhance anti-tumor efficacy in ovarian cancer
Proactive over reactive: the snare-based pretraction method improving the full-thickness resection of a large gastrointestinal stromal tumor
Targeted Anti‐Tumor Immunotherapy Using Tumor Infiltrating Cells
TH9 cells in anti-tumor immunity
Reversible acute blindness in suspected metformin-associated lactic acidosis: a case report
Targeting tumor cells with antibodies enhances anti-tumor immunity
Melatonin: an anti-tumor agent for osteosarcoma
Golimumab: A Novel Anti-Tumor Necrosis Factor
Tumor ablation induced anti-tumor immunity: destruction of the tumor in situ with the aim to evoke a robust anti-tumor immune response
Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC
Estrogen/ER in anti-tumor immunity regulation to tumor cell and tumor microenvironment
Targeting CD73 limits tumor progression and enhances anti-tumor activity of anti-PD-1 therapy in intrahepatic cholangiocarcinoma
Anti-PD-1 antibody armored γδ T cells enhance anti-tumor efficacy in ovarian cancer
Proactive over reactive: the snare-based pretraction method improving the full-thickness resection of a large gastrointestinal stromal tumor
Targeted Anti‐Tumor Immunotherapy Using Tumor Infiltrating Cells
TH9 cells in anti-tumor immunity
Reversible acute blindness in suspected metformin-associated lactic acidosis: a case report
Targeting tumor cells with antibodies enhances anti-tumor immunity
Melatonin: an anti-tumor agent for osteosarcoma
Golimumab: A Novel Anti-Tumor Necrosis Factor
Tumor ablation induced anti-tumor immunity: destruction of the tumor in situ with the aim to evoke a robust anti-tumor immune response
Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC